This week, we were fortunate to catch up with Professor Kelly Chibale, Principal Investigator at the University of Cape Town, founder of Africa’s first drug discovery and development centre, H3D, and one of the speakers at our #ScienceAfrica UnConference this year. Professor Chibale spoke eloquently about his efforts to create novel medicines to combat the major diseases in Africa as well as his concerted advocacy for greater investment in hard scientific infrastructure.
The University of Pretoria (UP) will host its first Community of Practice (CoP) focusing specifically on Malaria Elimination in the UP Institute for Sustainable Malaria Control (UP ISMC). This NRF initiative endeavours to provide ‘vehicles to enable the implementation of integrated trans-disciplinary and multi-disciplinary solutions to address societal challenges and to ultimately bring change to the lives of South Africans.
Postdoctoral research fellow Dr Mathew Njoroge at UCT’s Drug Discovery and Development Centre (H3D) recently returned from the 67th Lindau Nobel Laureate Meeting in Germany. The annual scientific conferences have been held in Lindau since 1951, bringing together Nobel laureates and young scientists to foster scientific exchanges between different generations and cultures.
There is a great need to fund talented African scientists — based in Africa — to succeed, rather than just survive, by providing world-class infrastructure. The continent is also facing a lack of scientific entrepreneurship and poorly developed scientific networks between different groups.
Researcher Professor Kelly Chibale has called for a deep commitment to investing in world-class infrastructure and skills for scientists to succeed on the continent.
Leading African researcher Professor Kelly Chibale has called for a deep commitment to investing in world-class infrastructure and skills to enable scientists to succeed on the continent..
Production of drugs in SA instead of outsourcing to countries such as India would dent high unemployment.
Public-private partnerships in the pharmaceutical sector are vital for accelerating job creation and infrastructure development in SA, says malaria researcher Kelly Chibale.
An exciting new antimalarial drug candidate is active across the entire parasite life cycle and holds great promise as a single-dose cure.
A new paper published today in the prestigious journal Science Translational Medicine describes the discovery and biological profiling of an exciting new antimalarial clinical drug candidate. MMV390048 is effective against resistant strains of the malaria parasite and across the entire parasite life cycle, and it has the potential to cure and protect in a single dose.
A new paper published today in the prestigious journal Science Translational Medicine describes the discovery and biological profiling of an exciting new anti-malarial clinical drug candidate, MMV390048, effective against resistant strains of the malaria parasite, and across the entire parasite lifecycle, with the potential to cure and protect in a single dose. The research was conducted by the University of Cape Town (UCT)'s Drug Discovery and Development Centre, H3D, and Medicines for Malaria Venture (MMV), in collaboration with a team of international researchers.
The scientist poised to save millions from the devastation of malaria
Africa has been at the mercy of Malaria for thousands of years. Killing half a million people on the continent each year, the disease is yet to meet its equal. But this could soon change. A team of young scientists at UCT has uncovered a compound that has the potential to attack Malaria at all three stages of its cycle through the human body, with a force beyond anything in modern medicine.
Professor Dame Sally Davies, the Chief Medical Officer for England and UK government adviser, has appointed an expert advisory board to support the Global Antimicrobial Resistance Innovation Fund (GAMRIF).
The 12 member board will advise how the UK can best spend an additional £50 million over the next 5 years to work with global partners to fund innovative initiatives to tackle drug resistant infections, which includes resistance to antibiotics.
The UK government has appointed an expert advisory board to advise how it can best spend an additional 50 million British pounds over the next five years to fund innovative initiatives to tackle drug resistant infections, which include resistance to antibiotics.
Professor Kelly Chibale, founder and director of the University of Cape Town’s Drug Discovery and Development Centre (H3D) and founding director of the South African Medical Research Council/UCT drug discovery and development research unit, has been selected as a member of the advisory board.